Chapel Hill bisphenol A expert panel consensus statement: Integration of mechanisms, effects in animals and potential to impact human health at current levels of exposure Saal, Frederick S. vom Akingbemi, Benson T. Belcher, Scott Birnbaun, Linda S. Crain, D. Andrew Eriksen, Marcus Farabollini, Francesca Guillette, Louis J. Hauser, Russ Heindel, Jerrold J. Ho, Shuk-Mei Hunt, Patricia A. Iguchi, Taisen Jobling, Susan Kanno, Jun Keri, Ruth A. Knudsen, Karen E. Laufer, Hans LeBlanc, Gerald A. Marcus, Michele McLachlan, John A. Myers, John Peterson Nadal, Ángel Newbold, Retha R. Olea Serrano, Nicolás Prins, Gail S. Richter, Catherine A. Rubin, Beverly S. Sonnenschein, Carlos Soto, Ana M. Talsness, Chris E. Vandenbergh, John G. Vandenberg, Laura N. Walser-Kuntz, Debby R. Watson, Cheryl S. Welshons, Wade V. Wehterill, Yelena Zoeller, Thomas R. Bisphenol A In vitro In vivo Rat Mouse Aquatic animal Cancer Low dose Non-monotonic dose-response curves Developmental programming This document is a summary statement of the outcome from the meeting: “Bisphenol A: An Examination of the Relevance of Ecological, In vitro and Laboratory Animal Studies for Assessing Risks to Human Health” sponsored by both the NIEHS and NIDCR at NIH/DHHS, as well as the US-EPA and Commonweal on the estrogenic environmental chemical bisphenol A (BPA, 2,2-bis(4-hydroxyphenyl)propane; CAS# 80-05-7). The meeting was held in Chapel Hill, NC, 28–30 November 2006 due to concerns about the potential for a relationship between BPA and negative trends in human health that have occurred in recent decades. Examples include increases in abnormal penile/urethra development in males, early sexual maturation in females, an increase in neurobehavioral problems such as attention deficit hyperactivity disorder (ADHD) and autism, an increase in childhood and adult obesity and type 2 diabetes, a regional decrease in sperm count, and an increase in hormonally mediated cancers, such as prostate and breast cancers. Concern has been elevated by published studies reporting a relationship between treatment with “low doses” of BPA and many of theses negative health outcomes in experimental studies in laboratory animals as well as in vitro studies identifying plausible molecular mechanisms that could mediate such effects. Importantly, much evidence suggests that these adverse effects are occurring in animals within the range of exposure to BPA of the typical human living in a developed country, where virtually everyone has measurable blood, tissue and urine levels of BPA that exceed the levels produced by doses used in the “low dose” animal experiments. 2013-04-26T10:06:29Z 2013-04-26T10:06:29Z 2007 journal article Saal, F.S.; et al. Chapel Hill bisphenol A expert panel consensus statement: Integration of mechanisms, effects in animals and potential to impact human health at current levels of exposure. Reproductive Toxicology, 24(2): 131-138 (2007). [http://hdl.handle.net/10481/24820] 0890-6238 doi: 10.1016/j.reprotox.2007.07.005 PMCID: PMC2967230 NIHMSID: NIHMS206975 http://hdl.handle.net/10481/24820 eng http://dx.doi.org/10.1016/j.reprotox.2007.07.005 http://creativecommons.org/licenses/by-nc-nd/3.0/ open access Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License Elsevier